Anti-Human CD87/PLAUR/uPAR Antibody (8B12)

Catalog No.

RHF99103

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

PLAUR, MO3, uPAR, CD87, Urokinase plasminogen activator surface receptor, Monocyte activation antigen Mo3

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q03405

Applications

ELISA, SPR

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

8B12

HIV-Tat upregulates the expression of senescence biomarkers in CD4+ T-cells., PMID:40342418

Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma., PMID:40317602

Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study., PMID:40275185

Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer., PMID:40154091

Analysis of the Predictive Efficacy of Serum suPAR Combined with APN and IgE Test and the Relationship of Patients with CHF and Cardiac Function., PMID:38581326

Analysis of Circulating Tumor and Cancer Stem Cells Provides New Opportunities in Diagnosis and Treatment of Small Cell Lung Cancer., PMID:36142766

Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome., PMID:35102231

Mitofusin-2 regulates leukocyte adhesion and β2 integrin activation., PMID:34494308

A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma., PMID:33561783

Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study., PMID:32706905

Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions., PMID:32069085

Soluble Urokinase Receptor and Acute Kidney Injury., PMID:31995687

Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes., PMID:31449183

Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer., PMID:31176112

Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins αMβ2 and αVβ3., PMID:29852400

Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis., PMID:26622860

Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography., PMID:26504891

Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation., PMID:25659907

Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese., PMID:25500737

Ex vivo paracrine properties of cardiac tissue: Effects of chronic heart failure., PMID:25175803

Cadmium induces urokinase-type plasminogen activator receptor expression and the cell invasiveness of human gastric cancer cells via the ERK-1/2, NF-κB, and AP-1 signaling pathways., PMID:25069788

Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM)., PMID:24465541

Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy., PMID:23842190

Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2., PMID:23709605

Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells., PMID:22634564

Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration., PMID:22280367

Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor., PMID:22203761

Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation., PMID:21223347

A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis., PMID:20967855

Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy., PMID:18794071

Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro., PMID:18781095

Urokinase-type plasminogen activator receptor induces conformational changes in the integrin alphaMbeta2 headpiece and reorientation of its transmembrane domains., PMID:18644795

PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity., PMID:18387948

Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells., PMID:18247343

Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor., PMID:18245952

Serum markers for prostate cancer: a rational approach to the literature., PMID:18243505

Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression., PMID:18189329

Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells., PMID:17970088

uPA binding increases UPAR localization to lipid rafts and modifies the receptor microdomain composition., PMID:17963689

Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice., PMID:17723133

Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer., PMID:17706320

Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors., PMID:17686008

Urokinase receptor variants in tissue and body fluids., PMID:17682340

Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo., PMID:17549305

The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis., PMID:17517866

A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines., PMID:17509140

Characterization of the rat urokinase plasminogen activator receptor promoter in PC12 cells., PMID:17455298

[Membrane and cytoplasmic expression of urokinase-type plasminogen activator receptor in synovial tissues of rheumatoid arthritis patients]., PMID:17445440

The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells., PMID:17344041

Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy., PMID:17330942

Document Download

Anti-Human CD87/PLAUR/uPAR Antibody (8B12).pdf